Novavax (NVAX) 7-24-17

 Comments Off on Novavax (NVAX) 7-24-17
Jul 272017
 
Novavax (NVAX) 7-24-17

BioInvest News – NVAX – Delivers Some Positive Phase II Immunogenicity Data In COPD…Investors Wanted an RSV Update – NVAX reported top line data from the Phase II older adult safety and immunogenicity trial (E205) demonstrated the benefit of adjuvant formulations and two-dose regimens in patients with RSV and chronic obstructive pulmonary disease (COPD).

Ionis (IONS) 5-15-17

 Comments Off on Ionis (IONS) 5-15-17
May 152017
 
Ionis (IONS) 5-15-17

BioInvest News – IONS – Reports Positive TTR Data, Safety/Patient Death Causes Concern – IONS reported positive Phase III data for inotersen (TTR-Rx) NEURO-TTR results in familial amyloid polyneuropathy (FAP) patients showing a statistically significant benefit in the two co-primary endpoints of modified Neuropathy Impairment Score (mNIS+7, p<0.0001) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN, P=0.0006) post 15 months of treatment.

Sangamo (SGMO) 5-10-17

 Comments Off on Sangamo (SGMO) 5-10-17
May 102017
 
Sangamo (SGMO) 5-10-17

Breaking News – Sangamo Therapeutics (SGMO) – PFE Global Deal for Hemophilia A Has Many Positive Implications – In a very competitive bidding process SGMO has inked a significant global partnership with Pfizer, who brings a wealth of value to SGMO, and notably validates the latter company’s gene therapy platform.

The Medicines Company (MDCO) 04-26-17

 Comments Off on The Medicines Company (MDCO) 04-26-17
Apr 282017
 
The Medicines Company (MDCO) 04-26-17

BIOINVEST BREAKING NEWS – The Medicines Company (MDCO) – Inclisiran FDA Path Clear After End of Phase II Meeting – Lower Risk, Value Enhanced – The Medicines Company announced that the primary endpoint of the Phase III registrational trial will be LDL-C levels. This is a major positive for MDCO – significantly reduces the risk and increases the value of Inclisiran.

‘Access to Management’ Conference Call with Madrigal (MDGL)- 4-4-17

 Comments Off on ‘Access to Management’ Conference Call with Madrigal (MDGL)- 4-4-17
Apr 052017
 
'Access to Management' Conference Call with Madrigal (MDGL)- 4-4-17

BIOINVEST Access to Management Webinar – Madrigal (MDGL)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Madrigal.

Esperion (ESPR) 02-20-17

 Comments Off on Esperion (ESPR) 02-20-17
Mar 232017
 
Esperion (ESPR)  02-20-17

BIOINVEST BREAKING NEWS – Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval” – Raising BUY to 40 and TARGET PRICE to 60

This morning, ESPR announced that the FDA has confirmed that the bempedoic acid Phase III development program is adequate to support an approval prior to their CVOT results, lifting one of the largest overhangs on the stock, and creating a clear path to an earlier-than-expected approval.

Nektar (NKTR) 02-20-17

 Comments Off on Nektar (NKTR) 02-20-17
Mar 232017
 
Nektar (NKTR) 02-20-17

BIOINVEST BREAKING NEWS – Nektar (NKTR) – NKTR-181 Successful In Phase III SUMMIT-07 Trial & Sets The Stage For A Revolution In Pain Drugs – Raising BUY and TARGET PRICE

The SUMMIT-07 trial met its primary endpoint demonstrating highly significant improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Moreover, the safety and tolerability of ‘181 in SUMMIT supports its breakthrough profile for moderate-to-severe pain relief without the abuse and addiction that has caused the opioid epidemic of today

The Medicines Company (MDCO) 02-17-17

 Comments Off on The Medicines Company (MDCO) 02-17-17
Mar 232017
 
The Medicines Company (MDCO) 02-17-17

BIOINVEST BREAKING NEWS – The Medicines Company (MDCO) – FOURIER IS ACTUALLY MORE POSITIVE FOR INCLISIRAN THAN BEFORE – Being the first to market is sometimes a double edged sword and is certainly the case with the Amgen’s Repatha (and REGN/SNY’s Praluent). We were at the ACC where the FOURIER* data was presented on Friday.

The Medicines Company (MDCO) 02-02-17

 Comments Off on The Medicines Company (MDCO) 02-02-17
Feb 022017
 
The Medicines Company (MDCO) 02-02-17

BIOINVEST Update – The Medicines Company (MDCO) – Amgen’s FOURIER Outcomes Trial Successful – After the close, AMGN announced the long-awaited results of the outcomes trial with Repatha – its PCSK9 monoclonal antibody.

The Medicines Company (MDCO) 11-07-16

 Comments Off on The Medicines Company (MDCO) 11-07-16
Nov 082016
 
The Medicines Company (MDCO) 11-07-16

BIOINVEST Update – The Medicines Company (MDCO) – – Discontinues ‘216 – AHA Meeting Next Week

News – MDCO Stops MDCO-216 After Pilot Trial Unsuccessful – The pilot trial did not show efficacy – there was no positive effect on atherosclerosis. Safety was fine. The data calls into question the viability of APO-A1 Milano as a target and the positive implications of HDL as well.

Madrigal Pharmaceuticals (MDGL) 10-25-16

 Comments Off on Madrigal Pharmaceuticals (MDGL) 10-25-16
Oct 252016
 
Madrigal Pharmaceuticals (MDGL) 10-25-16

BIOINVEST Update – (New Recommendation) Madrigal Pharmaceuticals (MDGL) – Paul Friedman Is Back

NASH is a hot topic in Biotech since September when Allergan bought Tobira Therapeutics (TBRA) for a stunning $1.7 billion for a Phase II asset. The Tobira deal was done at a tremendous 500% premium and topped the $1.2 billion Gilead paid for a NASH drug candidate being developed by Nimbus Therapeutics.

‘Access to Management’ Conference Call with Anthera (ANTH) 9-1-16

 Comments Off on ‘Access to Management’ Conference Call with Anthera (ANTH) 9-1-16
Sep 012016
 
'Access to Management' Conference Call with Anthera (ANTH) 9-1-16

BIOINVEST Access to Management Webinar – Anthera (ANTH)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Anthera.

Ziopharm (ZIOP) (7-15-16)

 Comments Off on Ziopharm (ZIOP) (7-15-16)
Jul 152016
 
Ziopharm (ZIOP) (7-15-16)

BIOINVEST BREAKING NEWS – Special Update – Ziopharm (ZIOP) – 3 Patients Die In The IL-12 Trial. ZIOP is down sharply this morning (7/15) on the report that three patients have died in their ongoing multicenter Phase I trial of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.

‘Access to Management’ Conference Call with Novavax (NVAX) 6-3-16

 Comments Off on ‘Access to Management’ Conference Call with Novavax (NVAX) 6-3-16
Jun 072016
 
'Access to Management' Conference Call with Novavax (NVAX) 6-3-16

BIOINVEST Access to Management Webinar – Novavax (NVAX)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Novavax.

Ziopharm (ZIOP) (5-16-16)

 Comments Off on Ziopharm (ZIOP) (5-16-16)
May 172016
 
Ziopharm (ZIOP) (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ZIOP – Shows Rather Impressive Preclinical Data at ASGCT, Up Next Human Data at ASCO.
ZIOP was front and center at the 2016 Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington D.C. last week. The company presented exciting preclinical data for IL-12 in combo with a PD-1 that showed 100% survival. The non-viral Sleeping Beauty (SB) system was also on display. Read more…